CN114544790B - Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit - Google Patents
Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit Download PDFInfo
- Publication number
- CN114544790B CN114544790B CN202011341741.8A CN202011341741A CN114544790B CN 114544790 B CN114544790 B CN 114544790B CN 202011341741 A CN202011341741 A CN 202011341741A CN 114544790 B CN114544790 B CN 114544790B
- Authority
- CN
- China
- Prior art keywords
- depression
- lysophosphatidylethanolamine
- reagent
- application
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 title claims abstract description 31
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 title claims abstract description 29
- 238000001514 detection method Methods 0.000 title claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 5
- 210000002381 plasma Anatomy 0.000 title abstract description 23
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Abstract
The application discloses an application of a reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparing a depression detection kit, and belongs to the field of depression detection. The use of the application is based on the fact that there is a difference in lysophosphatidylethanolamine (22:5) in plasma between depressed patients and normal persons, which is sufficient for an accurate differentiation between depressed patients and normal persons. The application also discloses a detection kit based on the principle. The kit can realize quantifiable objective detection and has the advantages of sensitivity, rapidness and high reliability.
Description
Technical Field
The application belongs to the field of depression detection, and particularly relates to application of a reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of a depression detection kit.
Background
Depression is a major type of mood disorder, characterized by a significant and persistent depression in the mood. As one of the diseases with the highest disability rate in the world, the burden of depression patients on families, healthcare systems and society is enormous. It is estimated that up to 50% of 80 ten thousand suicide animals worldwide exist annually. Currently, the global depression patient population accumulates more than 3.5 hundred million people, and China has more than 5400 ten thousand people suffering from depression.
The depression has remarkable hereditary property, the hereditary rate reaches 30% -40%, and a plurality of hereditary factors are involved. It is also affected by a variety of non-genetic factors that increase the complexity of the pathogenesis of depression. The unclear pathogenesis causes that the diagnosis method for the disease is always remained on subjective observation levels such as a questionnaire scale, and lacks objective examination indexes, and meanwhile, the operation difficulty is high and the diagnosis period is long. Therefore, it is urgent to develop a sensitive, rapid, highly reliable diagnostic method or apparatus based on quantifiable objective indicators.
Lysophosphatidylethanolamine occurs naturally in animal cells or plant cells, mainly in egg yolk or brain cells. Lysophosphatidylethanolamine is derived from phosphatidylethanolamine, which is a phospholipid containing 2 fatty acids, and when phospholipase A2 acts on phosphatidylethanolamine, one fatty acid is removed to produce lysophosphatidylethanolamine. Lysophosphatidylethanolamine (22:5), is one of lysophosphatidylethanolamine, wherein the number before the colon in the brackets indicates the number of C atoms, and the number after the colon indicates the number of c=c double bonds. At present, no relationship between lysophosphatidylethanolamine (22:5) in blood and depression has been reported.
Disclosure of Invention
The application aims to solve the problems that: provides a new application of lysophosphatidylethanolamine (22:5) as a marker of depression.
The technical scheme of the application is as follows:
use of a reagent for detecting lysophosphatidylethanolamine (22:5) in plasma for the preparation of a depression detection kit.
Further, the reagent is a reagent for a liquid chromatography-mass spectrometry method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, a column, pure water-dissolved 0.1% formic acid and acetonitrile-dissolved 0.1% formic acid are also included.
Further, the detection standard of the kit is as follows: when lysophosphatidylethanolamine (22:5) is significantly higher in the subject's plasma than in healthy humans, the subject is judged to be likely to have depression.
A depression detection kit comprising reagents for detecting lysophosphatidylethanolamine (22:5) in plasma.
Further, the reagent is a reagent for a liquid chromatography-mass spectrometry method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, a column, pure water-dissolved 0.1% formic acid and acetonitrile-dissolved 0.1% formic acid are also included.
Further, the detection standard of the kit is as follows: when lysophosphatidylethanolamine (22:5) is significantly higher in the subject's plasma than in healthy humans, the subject is judged to be likely to have depression.
The key point of the application is that the level of human plasma lysophosphatidylethanolamine (22:5) is determined to be obviously related to depression, so that the risk of depression can be judged by detecting the level of human plasma lysophosphatidylethanolamine (22:5), and the specific means for detecting the lysophosphatidylethanolamine (22:5) can be any of various means disclosed in the prior art, and the detection of the embodiment of the application by adopting a liquid chromatography-mass spectrometry combination method is not meant to be limited to the method.
The application provides a novel depression detection marker and a novel depression detection kit, which can realize quantitative objective detection of depression and have the advantages of sensitivity, rapidness and high reliability.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the application as defined by the appended claims.
The above-described aspects of the present application will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present application is limited to the following examples only. All techniques implemented based on the above description of the application are within the scope of the application.
Drawings
Fig. 1: relative amounts of lysophosphatidylethanolamine (22:5) in depressed and normal control plasma; CON, control; MDD, depression.
Detailed Description
Example 1 Depression detection kit and method of use thereof
1. Composition of the kit
Standard pure liquid containing 12mg/ml plasma metabolism marker, 1C 8 BEH column (1.7 μm, 2.1X100 mm) and 1T 3 HSS column (1.8 μm, 2.1X100 mm), pure water dissolved 0.1% formic acid, acetonitrile dissolved 0.1% formic acid. Wherein the plasma metabolic marker is lysophosphatidylethanolamine (22:5).
2. Application method
(a) Injecting the prepared plasma sample into a chromatographic column through an automatic sampler, and separating metabolites in positive and negative ionization modes respectively under the specific chromatographic conditions that: mobile phase A is 0.1% formic acid dissolved in pure water; mobile phase B was 0.1% formic acid dissolved in acetonitrile. For the positive mode, the gradient initially starts at 10% b, increases linearly to 40% b in 4 minutes after 1 minute, then increases to 100% b in 12 minutes and remains for 5 minutes, then returns to the initial ratio balance for about 3 minutes. In negative mode, the gradient starts at 100% a, increases linearly to 40% b after 1 minute, then increases to 100% b in 9 minutes, and remains for 4 minutes, then returns to the initial ratio equilibrium for about 4 minutes. The column temperature was 55 ℃.
(b) The separated metabolites were imported into a liquid chromatograph-mass spectrometer Shimadzu LC (30 AD) -MS (TQ 8050) to acquire dynamic multi-reaction monitoring (MRM) data for validation, and the main parameters of the mass spectrum were the same as positive and negative modes: the flow rate of the heating gas is 10L/min; the flow rate of the dry gas flow is 10L/min; the flow rate of the atomized air flow is 3L/min; the DL temperature was 250 ℃; the temperature of the heating block is 400 ℃; the interface heater temperature was 300 ℃.
(c) Based on the relative concentrations of lysophosphatidylethanolamine (22:5), the subject was assessed for depression. Relative concentrations >0.013 judged high risk of depression.
The kit is designed based on the plasma metabolic marker provided by the application, and can be used for accurately diagnosing and accurately evaluating patients suffering from depression.
To demonstrate the effectiveness of lysophosphatidylethanolamine (22:5) in assessing depression, the present application provides the following experimental examples.
Experimental example 1 comparison of plasma lysophosphatidylethanolamine (22:5) concentration between depressed patients and normal controls
50 cases of clinical depression and normal control were collected, each of which was prepared as 5ml plasma samples. 100 samples were taken from a first hospital affiliated with Chongqing university, subjects in the depression group excluded from past or present suffering from other neurological or psychiatric disorders, alcoholism or dependence on illicit drug use or pregnancy, and were diagnosed as depression by a first hospital affiliated with Chongqing university using the DSM-IV-TR standard, and a Hamiltonian depression scale was implemented to assess the severity of depression. Normal control subjects were excluded from any past or present neurological disease, I-axis or II-axis disease or systemic medical disease. The study protocol fully met the ethical criteria of human trials and was approved by the ethical committee of Chongqing medical university, subjects were known prior to the test and were given written consent.
The plasma sample is tested for concentration of the plasma lysophosphatidylethanolamine (22:5) by the kit and the method of the embodiment 1, and the result is shown in figure 1, wherein the concentration of the plasma lysophosphatidylethanolamine (22:5) of a patient suffering from depression is obviously higher than that of a control (p<0.001 FDR of 0.0004, log) 2 |fc|= 0.5718. According to FIG. 1, the relative concentration of 0.013 can be used as a threshold for predicting depression>And 0.013 can judge that the risk of the detected person to suffer from depression is high.
Note that: FDR refers to false discovery rate, FDR of 0.0004 indicates that the expected value of the ratio of the number of false rejections (rejecting true (original) hypotheses) to the number of all rejected original hypotheses is 0.0004; FC refers to fold change.
The results of the experimental examples show that the plasma lysophosphatidylethanolamine (22:5) of the patients with depression is obviously higher than that of normal people, and the concentration of the plasma lysophosphatidylethanolamine (22:5) can be used for distinguishing the patients with depression from the normal people.
In conclusion, the kit provided by the application can be used for rapid auxiliary diagnosis of depression and has a good application prospect.
Claims (3)
1. Use of a reagent for detecting lysophosphatidylethanolamine (22:5) in plasma for the preparation of a depression detection kit, characterized in that:
the reagent is used for a liquid chromatography-mass spectrometry method;
or the reagent is a reagent for a liquid chromatography method.
2. The use according to claim 1, characterized in that: the kit comprises T 3 HSS chromatographic column, pure water dissolved 0.1% formic acid as mobile phase a and acetonitrile dissolved 0.1% formic acid as mobile phase B.
3. The use according to claim 1, characterized in that: the detection standard of the kit is as follows: when the plasma of the tested person is obviously higher than that of healthy people, the tested person is judged to be a high risk person of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011341741.8A CN114544790B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011341741.8A CN114544790B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114544790A CN114544790A (en) | 2022-05-27 |
| CN114544790B true CN114544790B (en) | 2023-10-24 |
Family
ID=81659360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011341741.8A Active CN114544790B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114544790B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115219705B (en) * | 2022-07-14 | 2023-04-07 | 中国医学科学院北京协和医院 | Application of biomarker in Cushing syndrome diagnosis |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007126398A (en) * | 2005-11-04 | 2007-05-24 | Gunma Prefecture | Neurotrophic agent and method for utilizing the same |
| JP2009148244A (en) * | 2007-11-29 | 2009-07-09 | Gunma Prefecture | Method for producing lysophosphatidylethanolamine |
| CN102445512A (en) * | 2010-10-09 | 2012-05-09 | 中国人民解放军第二军医大学 | Small molecule metabolite map for identifying liver cancer, hepatitis or liver cirrhosis and manufacturing method thereof |
| CN102639115A (en) * | 2009-09-15 | 2012-08-15 | 阿尔尼拉姆医药品有限公司 | Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes |
| CN104520313A (en) * | 2012-08-03 | 2015-04-15 | 巴斯夫植物科学有限公司 | Novel enzymes, enzyme components and uses thereof |
| WO2016112174A2 (en) * | 2015-01-08 | 2016-07-14 | The Trustees Of The University Of Pennsylvania | Biomarkers of Sleep Deprivation and Cognitive Impairment |
| CN106456664A (en) * | 2013-05-02 | 2017-02-22 | 牛津大学之校长及学者 | Lipidomic biomarkers |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| CN109946390A (en) * | 2017-12-20 | 2019-06-28 | 上海生物信息技术研究中心 | A kind of combination of pulmonary cancer diagnosis marker and application |
| CN110646554A (en) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | Pancreatic cancer diagnosis marker based on metabonomics and screening method and application thereof |
| CN110702930A (en) * | 2019-09-05 | 2020-01-17 | 首都医科大学附属北京安定医院 | Application of 24-hydroxycholesterol in preparation of depression diagnosis and treatment related products |
| CN110988351A (en) * | 2019-09-05 | 2020-04-10 | 首都医科大学附属北京安定医院 | Application of vascular cell adhesion molecule in preparation of depression diagnosis and treatment related products |
| TW202040130A (en) * | 2018-12-27 | 2020-11-01 | 公立大學法人奈良縣立醫科大學 | Method for diagnosing interstitial cystitis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151287A1 (en) * | 2015-11-30 | 2017-06-01 | Flagship Ventures Management, Inc. | Methods and compositions of chondrisomes |
| AU2017230870A1 (en) * | 2016-03-09 | 2018-10-04 | Cbmed Gmbh Center For Biomarker Research In Medicine | Biomarker for the diagnosis of pulmonary hypertension (PH) |
| WO2018009834A1 (en) * | 2016-07-07 | 2018-01-11 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
-
2020
- 2020-11-24 CN CN202011341741.8A patent/CN114544790B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007126398A (en) * | 2005-11-04 | 2007-05-24 | Gunma Prefecture | Neurotrophic agent and method for utilizing the same |
| JP2009148244A (en) * | 2007-11-29 | 2009-07-09 | Gunma Prefecture | Method for producing lysophosphatidylethanolamine |
| CN102639115A (en) * | 2009-09-15 | 2012-08-15 | 阿尔尼拉姆医药品有限公司 | Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes |
| CN102445512A (en) * | 2010-10-09 | 2012-05-09 | 中国人民解放军第二军医大学 | Small molecule metabolite map for identifying liver cancer, hepatitis or liver cirrhosis and manufacturing method thereof |
| CN104520313A (en) * | 2012-08-03 | 2015-04-15 | 巴斯夫植物科学有限公司 | Novel enzymes, enzyme components and uses thereof |
| CN106456664A (en) * | 2013-05-02 | 2017-02-22 | 牛津大学之校长及学者 | Lipidomic biomarkers |
| WO2016112174A2 (en) * | 2015-01-08 | 2016-07-14 | The Trustees Of The University Of Pennsylvania | Biomarkers of Sleep Deprivation and Cognitive Impairment |
| CN109946390A (en) * | 2017-12-20 | 2019-06-28 | 上海生物信息技术研究中心 | A kind of combination of pulmonary cancer diagnosis marker and application |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| TW202040130A (en) * | 2018-12-27 | 2020-11-01 | 公立大學法人奈良縣立醫科大學 | Method for diagnosing interstitial cystitis |
| CN110702930A (en) * | 2019-09-05 | 2020-01-17 | 首都医科大学附属北京安定医院 | Application of 24-hydroxycholesterol in preparation of depression diagnosis and treatment related products |
| CN110988351A (en) * | 2019-09-05 | 2020-04-10 | 首都医科大学附属北京安定医院 | Application of vascular cell adhesion molecule in preparation of depression diagnosis and treatment related products |
| CN110646554A (en) * | 2019-09-12 | 2020-01-03 | 北京博远精准医疗科技有限公司 | Pancreatic cancer diagnosis marker based on metabonomics and screening method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| "Discovery and Validation of Plasma Biomarkers for Major Depressive Disorder Classification Based on Liquid Chromatography−Mass Spectrometry";Liu XY. et al;《Journal of Proteome Research》;第14卷(第5期);第2323-2325页，附图3，表2 * |
| "Plasma lipidomics reveals potential lipid markers of major depressive disorder";Liu, XY et al;《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》;第408卷(第23期);第6497-6507页 * |
| "抑郁症组学生物标志物的研究进展";朱立静等;《中国医院药学杂志》;第36卷(第23期);第2131-2134页 * |
| "抑郁障碍血浆蛋白组学和代谢组学整合分析";桂思雯;《中国优秀学位论文全文数据库医药卫生科技》(第12期);第1-146页 * |
| "抗抑郁药物氟西汀和活性化合物油酰胺作用机制的代谢组学研究";郑姝宁;《中国优秀博士学位论文全文数据库医药卫生科技》(第7期);第1-141页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114544790A (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106979982B (en) | Method and kit for diabetes risk prediction and treatment evaluation | |
| WO2022213746A1 (en) | Method for diagnosing and treating white matter lesion, and application of the method | |
| WO2022206264A1 (en) | Method for diagnosing and treating white matter lesion and application | |
| WO2012000770A1 (en) | Methods to diagnose liver diseases | |
| JP2015231392A (en) | Metabolic biomarkers for autism | |
| Zhu et al. | Metabolomic analysis of exosomal-markers in esophageal squamous cell carcinoma | |
| JP2013512444A (en) | Means and methods for diagnosing multiple sclerosis | |
| CN114544790B (en) | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit | |
| US9529002B2 (en) | Biomarkers for prediction, diagnosis, and monitoring of Alzheimer's disease | |
| CN113447599B (en) | Biomarker for diagnosing cerebral infarction of patient with leukoencephalopathy and application of biomarker | |
| CN113624868A (en) | Biomarker combination for predicting or evaluating cognitive function of bipolar affective disorder patient and application thereof | |
| Al-Asmari et al. | Effects of postmortem interval, putrefaction, diabetes, and location of death on the analysis of ethyl glucuronide and ethyl sulfate as ethanol biomarkers of antemortem alcohol consumption | |
| CN114544821B (en) | Application of reagent for detecting phosphatidylethanolamine (36:4) in blood plasma in preparation of depression detection kit | |
| CN114544822B (en) | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit | |
| CN114544826B (en) | Application of reagent for detecting histidine in blood plasma in preparation of depression detection kit | |
| JP2014517300A (en) | Method for diagnosing multiple sclerosis | |
| JP5068819B2 (en) | Means and methods for examining hemolytic anemia | |
| CN116519812A (en) | Application of biomarker in preparation of gestational diabetes diagnostic reagent | |
| CN114544825A (en) | Application of reagent for detecting lysophosphatidylcholine (16:1) in plasma in preparation of depression detection kit | |
| JP6222629B2 (en) | Biomarkers for dysuria | |
| CN102105793A (en) | Means and methods for assessing liver enzyme induction | |
| US20140322734A1 (en) | Biomarkers for prediction, diagnosis, and monitoring of parkinson's disease | |
| RU2818128C2 (en) | Method for diagnosing mental disorders by blood lipids | |
| US20210048444A1 (en) | Method for establishing the presence and progression of neurodegenerative disease | |
| Ko et al. | Breath gas analysis for a potential diagnostic method of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |